A foot-and-mouth disease virus O type and A type antibody joint detection kit and its preparation method and application

By developing O-type and A-type antibody joint detection kits for foot-and-mouth disease viruses, combined with enzyme label reagents and quality control products, the problems of poor detection complexity and repetition in the existing technology have been solved, and high sensitivity and specific detection have been achieved. In various application scenarios.

CN114578047BActive Publication Date: 2024-11-12LUOYANG PULIKE WANTAI BIOTECH
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202011379112.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-11-30
Publication Date
2024-11-12
Estimated Expiration
2040-11-30

AI Technical Summary

Technical Problem

The existing foot-and-mouth disease virus antibody detection methods have complex operation, long time consumption, biosafety risks, poor repetition and the inability to detect O and A antibodies at the same time, which affects the diagnosis and prevention of the disease.

Method used

A joint detection kit for foot-and-mouth disease virus type O and A antibodies was developed, using an enzyme label kit to combine quality control products, including a specific amount of foot-and-mouth virus antigen, monoclonal antibodies and goat anti-mouse polyclonal antibodies, and optimized antigen coating. The amount and enzyme-label reagent components can achieve high sensitivity and specific detection, reduce the need for negative controls and positive controls, and simplify the operation process.

Benefits of technology

It realizes rapid, accurate and convenient simultaneous detection of O and A antibodies, reduces laboratory operation risks, improves detection efficiency and repeatability, and is suitable for non-immune diagnosis, especially for epidemiological analysis and vaccine quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114578047B_ABST
    Figure CN114578047B_ABST
Patent Text Reader

Abstract

The present invention provides an antibody joint detection kit for foot-and-mouth disease virus type O and type A, the antibody joint detection kit comprises foot-and-mouth disease virus type O and type A antibody detection chips, enzyme-labeled reagents, the spotting points on the foot-and-mouth disease virus type O and type A antibody detection chips are respectively coated with foot-and-mouth disease virus type O antigen, foot-and-mouth disease virus type A antigen, quality control products, and blank controls; the O-type foot-and-mouth disease virus antigen is an O-type foot-and-mouth disease virus-like particle, the A-type foot-and-mouth disease virus antigen is an A-type foot-and-mouth disease virus-like particle, the quality control product is a sheep anti-mouse polyclonal antibody, the blank control is a spotting liquid, and the enzyme-labeled reagent is a solution containing enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 and enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4. The antibody joint detection kit of the present invention not only has high sensitivity, but also overcomes the defect of large differences in detection results between different batches in the prior art, and can be effectively used in a variety of non-immune diagnostic applications such as vaccine quality control.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a foot-and-mouth disease virus O-type and A-type antibody joint detection kit and a preparation method and application thereof, belonging to the field of biomedicine. Background Art

[0002] Foot-and-mouth disease is a febrile, acute, highly contagious disease that even-toed ungulates are susceptible to, caused by infection with the foot-and-mouth disease virus. The disease spreads rapidly and has a high incidence rate. The outbreak and prevalence of the disease have caused huge economic losses to the global breeding industry. It is listed as the first of Class A severe infectious diseases by the World Organization for Animal Health (OIE) and the Food and Agriculture Organization of the United Nations (FAO), and my country lists it as the first of Class I infectious diseases. The foot-and-mouth disease virus is divided into 7 serotypes and more than 80 subtypes, which are very easy to mutate. Among them, the 7 serotypes include type A, type O, Asia I, type C, type SAT1, type SAT2, and type SAT3. Type O and type A foot-and-mouth disease viruses are the most widespread. According to genetic classification, there are three main genetic topological types (Topotype) of type O foot-and-mouth disease virus, which belong to CATHAY type (Chinese type), ME-SA type (Middle East-South Asia type) and SEA type (Southeast Asia type). Since there is no cross-immune protection between different types of vaccines, the antigenicity of different subtypes within the same serotype O also varies to varying degrees, and the degree of serological cross-reaction of the antibodies they produce is also different. This requires that the antibody detection method must be specific and stable.

[0003] At present, the prevention and control of foot-and-mouth disease is mainly based on vaccine immunization, and monitoring of antibody levels after vaccine immunization is a necessary measure to control the effect of vaccine immunization. The commonly used foot-and-mouth disease serological detection methods on the market are mainly: virus neutralization test (VNT) and liquid phase blocking ELISA method (LPB-ELISA). Among them, the virus neutralization test is the gold standard for antibody determination, but this method requires the use of live viruses and can only be performed in specific high-level laboratories. The operation is relatively complicated, takes about 5 days, and there are biosafety risks; the liquid phase blocking ELISA kit is a commercial kit with relatively more applications, but the operation steps are cumbersome, takes about 4 hours, and the test results between batches are unstable. In addition, the capture antibody and enzyme-labeled antibody of the kit are all polyclonal antibodies, and polyclonal serum often has uneven quality, which affects the test results. In addition, the above methods are all single-index detection, and can only detect one antibody at a time, and the sample detection volume is large and time-consuming and labor-intensive. Therefore, it is of great significance to develop a kit that can directly prepare antigen plates with solid phase antigens and detect FMDV O-type and A-type antibodies at the same time, solve the problem of poor repeatability, and improve sensitivity and specificity, which is of great significance for the diagnosis and prevention of the disease. Summary of the invention

[0004] In order to solve the deficiencies of the prior art, the present invention provides a foot-and-mouth disease virus O type and A type antibody joint detection kit, wherein the antibody joint detection kit comprises one or more foot-and-mouth disease virus O type and A type antibody detection chips, and enzyme-labeled reagents; the spot points on the foot-and-mouth disease virus O type and A type antibody detection chips are respectively coated with foot-and-mouth disease virus O type antigen, foot-and-mouth disease virus A type antigen, quality control products, and blank controls; the O type foot-and-mouth disease virus antigen is an O type foot-and-mouth disease virus-like particle, and the A type foot-and-mouth disease virus antigen is an A type foot-and-mouth disease virus-like particle The quality control product is a sheep anti-mouse polyclonal antibody, the blank control is a spotting solution, the enzyme-labeled reagent is a solution containing an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody and an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody, the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody is an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 or an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 6G6, and the enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody is an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4 or an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 2E11.

[0005] As an embodiment of the present invention, in the antibody joint detection kit described in the present invention, the coating amount of the O-type foot-and-mouth disease virus antigen is 1 to 128 ng / spot; the coating amount of the A-type foot-and-mouth disease virus antigen is 1 to 128 ng / spot; the heavy chain variable region of the O-type foot-and-mouth disease virus monoclonal antibody 7D2 is encoded by SEQ.ID NO.7 or its degenerate sequence, and the light chain variable region is encoded by SEQ.ID NO.8 or its degenerate sequence; the heavy chain variable region of the O-type foot-and-mouth disease virus monoclonal antibody 6G6 is encoded by SEQ.ID NO.5 or its degenerate sequence, and the light chain variable region is encoded by SEQ.ID NO.6 or its degenerate sequence; the heavy chain variable region of the A-type foot-and-mouth disease virus monoclonal antibody 3B4 is encoded by SEQ.ID NO.3 or its degenerate sequence, and the light chain variable region is encoded by SEQ.ID NO.4 or its degenerate sequence; the heavy chain variable region of the A-type foot-and-mouth disease virus monoclonal antibody 2E11 is encoded by SEQ.ID NO.1 or its degenerate sequence, and the light chain variable region is encoded by SEQ.ID NO.2 or its degenerate sequence encoding; the buffer used for the enzyme-labeled reagent is a PBS solution containing 20% ​​fetal bovine serum by volume, wherein the final concentrations of the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 and the enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4 are 100ng / ml and 75ng / ml respectively; the enzyme labeled by the enzyme-labeled reagent is horseradish peroxidase, alkaline phosphatase or β-D-galactosidase; the quality control sample is spotted at quality control sample points 1 to 3. The coating amount of the quality control point 1 is greater than or equal to 1 ng / spot and less than 4 ng / spot; the coating amount of the quality control point 2 is 4 ng / spot; the coating amount of the quality control point 3 is greater than 4 ng / spot and less than or equal to 6 ng / spot; the spotting solution is a mixture of 5% glycerol solution, 5% sorbitol solution, 0.05% Triton solution, DMSO solution, and PBS (pH 6.8) solution in a volume ratio of 10:15:0.1:50:100.

[0006] By further optimizing and selecting the above-mentioned antigen coating amount, high sensitivity of detection is ensured.

[0007] Through experimental research, the present invention defines a specific coating amount of type A foot-and-mouth disease virus antigen, a specific coating amount of type O foot-and-mouth disease virus antigen, a specific coating amount of goat anti-mouse polyclonal antibody, a specific enzyme-labeled type A foot-and-mouth disease virus monoclonal antibody content, and a specific enzyme-labeled type O foot-and-mouth disease virus monoclonal antibody content, thereby achieving high-sensitivity detection of serum antibodies in samples.

[0008] Compared with the traditional ELISA kits, which are all equipped with negative controls, positive controls or standard products as quality control products in the kits, the joint test kit of the present invention is equipped with quality control products on the reaction carrier through technical improvement, and the quality control products are commercial sheep anti-mouse polyclonal antibodies, and there is no need to set negative controls and positive controls in the kits, that is to say, not only do they not need to screen animals in advance for immunization or virus attack, collect serum and other cumbersome preparation steps and manpower and animal test site costs, but also greatly improve the convenience and accuracy of the kit operation. In particular, it avoids the trouble of a class of infectious viruses, namely foot-and-mouth disease viruses, which must be operated in high-level laboratories. The present invention has been found through research that sheep anti-mouse polyclonal antibodies of a specific content can be used as quality control products, without the need to set negative controls and positive controls. The role of sheep anti-mouse polyclonal antibodies is to serve as a reaction control when there is no antibody reaction in a single detection well, which is used to evaluate the effectiveness of the test and reflect the reaction degree of the enzyme-labeled reagent when there is no blocking. The sheep anti-mouse polyclonal antibodies can be purchased commercially or prepared by conventional methods, and are easy to operate. The present invention has been found through research that sample diluents with specific contents and components improve the detection sensitivity and specificity of the kit.

[0009] As a preferred embodiment of the present invention, in the antibody joint test kit described in the present invention, the coating amount of the O-type foot-and-mouth disease virus antigen is 8-32 ng / point; the coating amount of the A-type foot-and-mouth disease virus antigen is 16-64 ng / point; the coating amount of the sheep anti-mouse polyclonal antibody of the quality control points 1 to 3 is 2 ng / point, 4 ng / point and 6 ng / point respectively.

[0010] As a more preferred embodiment of the present invention, in the antibody joint detection kit of the present invention, the coating amount of the O-type foot-and-mouth disease virus antigen is 16 ng / spot.

[0011] As a more preferred embodiment of the present invention, in the antibody joint detection kit of the present invention, the coating amount of type A foot-and-mouth disease virus antigen is 32 ng / spot.

[0012] As a most preferred embodiment of the present invention, in the antibody joint test kit described in the present invention, the coating amount of the foot-and-mouth disease virus type O antigen in the antibody joint test kit for foot-and-mouth disease virus type O and type A is 16 ng / spot, and the coating amount of the foot-and-mouth disease virus type A antigen is 32 ng / spot.

[0013] As a preferred embodiment of the present invention, in the antibody joint detection kit of the present invention, the enzyme-labeled reagent is a solution containing enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 and enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4.

[0014] As an embodiment of the present invention, in the antibody joint detection kit described in the present invention, the kit further comprises a sample diluent, a substrate solution, and a washing solution; the sample diluent is a PBS solution containing 10% V / V fetal bovine serum, 0.05% to 0.2% V / V Triton-100, and 0.1% V / V Proclin300; the substrate solution is a TMB (3,3',5,5'-tetramethylbenzidine) solution; and the washing solution is a PBS solution containing 1% V / V Tween 20.

[0015] As a preferred embodiment of the present invention, in the antibody joint detection kit of the present invention, the sample diluent is a PBS solution containing 10% V / V fetal bovine serum, 0.1% V / V Triton-100, and 0.1% V / V Proclin300.

[0016] The content of Triton-100 contained in the sample treatment solution can be 0.05% V / V, 0.06% V / V, 0.07% V / V, 0.08% V / V, 0.09% V / V, 0.1% V / V, 0.11% V / V, 0.12% V / V, 0.13% V / V, 0.14% V / V, 0.15% V / V, 0.16% V / V, 0.17% V / V, 0.18% V / V, 0.19% V / V, or 0.2% V / V.

[0017] The present invention ensures higher detection sensitivity by further optimizing the components and contents in the substrate liquid and the washing liquid.

[0018] As an embodiment of the present invention, in the antibody joint detection kit described in the present invention, the coating amounts of the sheep anti-mouse polyclonal antibody of the quality control point (1), the quality control point (2), and the quality control point (3) in the detection chip are 2ng / point, 4ng / point, and 6ng / point, respectively; the blank control spot (4) is a background detection spot; the foot-and-mouth disease virus type A antigen is spotted at the spot (5); and the foot-and-mouth disease virus type O antigen is spotted at the spot (6); the quality control point (1), the quality control point (2), the quality control point (3), and the blank control spot (4) are respectively located at the upper left corner, lower left corner, lower right corner, and upper right corner of the detection chip; the points (5) and (6) can be respectively located at other positions of the detection chip; the spot points (1) to (6) are respectively located at the upper left corner, lower left corner, lower right corner, and upper right corner of the detection chip; The distance between the midpoint and the edge of the point is ≥700 μm; the distances from the quality control point (1), the quality control point (2), the quality control point (3), and the blank control sample point (4) to the upper edge and lower edge of the detection chip subunit are ≥8 mm, and the distances to the left edge and right edge of the detection chip subunit are ≥5 mm; the antibody joint detection kit comprises one or more subunits of the foot-and-mouth disease virus type O and type A antibody detection chip, and is composed of a bottom end, an upper grid, and a detection chip clamped therebetween by the bottom end and the upper grid to form an independent detection hole, wherein one detection hole corresponds to one detection chip subunit, and when the antibody joint detection kit comprises a plurality of foot-and-mouth disease virus type O and type A antibody detection chip subunits, each of the independent detection chip subunits is integrated into a microarray chip.

[0019] The present invention also provides a method for preparing the antibody joint detection kit for foot-and-mouth disease virus type O and type A, wherein the method comprises: step (1) preparing foot-and-mouth disease virus type O antigen and foot-and-mouth disease virus type A antigen respectively, diluting them with spotting solution together with sheep anti-mouse polyclonal antibodies, and spotting them on a membrane to prepare an antibody detection chip for foot-and-mouth disease virus type O and type A; step (2) forming an independent detection hole with a bottom end, an upper grid, and the antibody detection chip of step (1) arranged therebetween, wherein the antibody detection chip is arranged between the bottom end and the upper grid and clamped by the bottom end and the upper grid, wherein one detection hole corresponds to one detection chip subunit, and when the antibody joint detection kit comprises a plurality of antibody detection chip subunits for foot-and-mouth disease virus type O and type A, each of the detection holes corresponds to one detection chip subunit. The independent detection chip subunits are integrated into a microarray chip; step (3) using enzymes to respectively label the O-type foot-and-mouth disease virus monoclonal antibody 7D2 and the A-type foot-and-mouth disease virus monoclonal antibody 3B4, diluting them with enzyme-labeled diluent to final concentrations of 100 ng / ml and 75 ng / ml respectively and then mixing them evenly to use as enzyme-labeled reagents, wherein the enzyme-labeled diluent is a PBS solution containing a final volume of 20% V / V fetal bovine serum; step (4) preparing a sample diluent, a washing solution, and a substrate solution; and step (5) assembling the O-type and A-type foot-and-mouth disease virus antibody detection chip subunits or their subunit microarray chips prepared in step (2), the enzyme-labeled reagent prepared in step (3), and the sample diluent, the washing solution, and the substrate solution prepared in step (4) into the antibody joint detection kit.

[0020] As an embodiment of the present invention, in the method for preparing the antibody joint detection kit for foot-and-mouth disease virus type O and type A, the spotting solution in step (1) is prepared by mixing 5% glycerol solution, 5% sorbitol solution, 0.05% Triton solution, DMSO solution, and PBS (pH 6.8) solution in a volume ratio of 10:15:0.1:50:100; the goat anti-mouse polyclonal antibody is diluted to 100 μg / ml, 200 μg / ml, and 300 μg / ml respectively with the spotting solution, and the solution is used as the quality control spotting solution and is spotted at points (1), (2), and (3) respectively; the spotting solution is used as a blank control and is spotted at point (4), the foot-and-mouth disease virus type A antigen is spotted at spotting point (5), and the foot-and-mouth disease virus type O antigen is spotted at spotting point (6); the quality control product spot (1) is used as a blank control and is spotted at point (4), the foot-and-mouth disease virus type A antigen is spotted at spotting point (5), and the foot-and-mouth disease virus type O antigen is spotted at spotting point (6); ), the quality control product point (2), the quality control product point (3), and the blank control spot point (4) are respectively located at the upper left corner, lower left corner, lower right corner, and upper right corner of the detection chip, and the points (5) and (6) can be spotted at other positions of the detection chip, respectively. The distance between the midpoint of the spot points (1) to (6) and the edge of the point is ≥700μm; the distance between the quality control product point (1), the quality control product point (2), the quality control product point (3), and the blank control point (4) to the upper edge and lower edge of the detection chip subunit is ≥8mm, and the distance to the left edge and right edge of the detection chip subunit is ≥5mm; the enzyme label diluent of step (3) is a PBS solution containing 20% ​​V / V fetal bovine serum; the sample diluent of step (4) is a PBS solution containing 10% V / V fetal bovine serum, 0.05% to 0.2% V / V The PBS solution contains Triton-100 and 0.1% V / V Proclin 300; the washing solution contains 1% V / V Tween 20 in PBS; and the substrate solution contains TMB (3,3',5,5'-tetramethylbenzidine) solution.

[0021] The spotting volume of the A-type foot-and-mouth disease virus antigen and the O-type foot-and-mouth disease virus antigen is 20 nl / spot.

[0022] As a preferred embodiment of the present invention, in the method for preparing the antibody joint detection kit for foot-and-mouth disease virus type O and type A, the sample diluent is a PBS solution containing 10% V / V fetal bovine serum, 0.1% V / V Triton-100, and 0.1% V / V Proclin300.

[0023] The present invention also provides the use of the antibody joint detection kit in the preparation of non-immune diagnosis.

[0024] As an embodiment of the present invention, the antibody joint detection kit of the present invention is used in the preparation of non-immune diagnosis, and the application in non-immune diagnosis includes epidemiological analysis, qualitative foot-and-mouth disease virus type O and type A antibody detection of in vitro serum, international live pig, cattle and sheep trade, import and export inspection and quarantine, and foot-and-mouth disease virus type O and type A vaccine quality control.

[0025] The present invention also provides an application method of the combined detection kit, which comprises:

[0026] Step (1) Sample pre-dilution: dilute the serum sample 10 times with sample diluent;

[0027] Step (2) numbering: numbering the chip wells according to the sample sequence;

[0028] Step (3) Infiltration: add 300 μl / well of washing solution, infiltrate for 3 minutes, discard the solution and pat dry;

[0029] Step (4) adding the diluted sample at 50-100 μl / well and incubating in a constant temperature oscillator at 37° C. and 500 rpm for 30 minutes;

[0030] Step (5) adding enzyme labeling reagent, adding 50-100 μl / well of enzyme labeling reagent, placing in a constant temperature oscillator at 37° C. and 500 rpm for incubation for 30 minutes; discarding the liquid, adding 300 μl / well of washing solution, soaking for 10-20 seconds, discarding the liquid, and repeatedly washing 5 times, and patting dry for the last time;

[0031] Step (6) color development, add 100 μl / well of substrate solution, and incubate at 37°C for 15 minutes;

[0032] In step (7), the liquid is discarded vertically, shaken off, and after removing the chip cover, the chip is turned upside down on a dust-free paper and pressed gently. The result is measured using a microplate chip imager within 10 minutes, and the blocking rate (1-sample gray value / quality control point gray value) is derived.

[0033] Test validity determination: The gray value of the quality control point should be ≥10000, and the gray value of the blank control point should be ≤3000, otherwise the test is invalid. This determination is completed automatically by the internal data processing and analysis system. The results determination (this determination is also completed automatically by the internal one-key intelligent data processing and analysis system, and no technical personnel are required to perform data calculations and statistical analysis) standards are as follows:

[0034] Calculation of blocking rate: blocking rate = (1-sample gray value / quality control point gray value) × 100%

[0035] Positive determination: FMDV O and A antibodies are positive when the blocking rate is ≥50%;

[0036] Negative determination: When the blocking rate is less than 50%, FMDV O and A antibodies are negative.

[0037] The advantages of the present invention are:

[0038] Unlike traditional ELISA kits, the kit described in the present invention has a quality control product on the reaction carrier through technological improvement, and the quality control product is a commercial sheep anti-mouse polyclonal antibody. There is no need to set up negative control and negative control in the kit. In other words, not only is there no need for tedious preparation steps such as pre-screening animals for immunization or virus attack, collecting serum, and the cost of manpower and animal testing sites, but the convenience and accuracy of the kit operation are also greatly improved.

[0039] The combined test kit prepared by the present invention has highly integrated detection items, rapid detection, simple operation, and one-click intelligent data processing, which eliminates the tedious data processing and large-scale data analysis after conventional method detection, makes it easier to control the health status of the pig herd and facilitates intensive management of the breeding industry.

[0040] The combined test kit prepared by the present invention has accurate and reliable results, good repeatability, and only takes about 1.5 hours to detect. It can be used to detect a series of sera collected after vaccine immunization to evaluate the immune protection effect of the vaccine. It can be used to simultaneously detect O-type and A-type antibodies in clinical pig, cattle and sheep sera for epidemiological surveys. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 This is a schematic diagram of the spotting pattern of each chip hole on the O-type and A-type foot-and-mouth disease virus antibody detection chip. Figure 1 A, B, C, D, E, F, G, H, I, and J represent different spotting patterns, and in the same figure, the specific positions of 5 and 6 on the detection chip are interchangeable;

[0042] Figure 2 The kits have three different numbers of O-type and A-type foot-and-mouth disease virus antibody detection chip subunits. The partial enlarged image shows a detection chip of an O-type and A-type foot-and-mouth disease virus antibody detection chip subunit. Figure 2 O, P, and Q represent test kits with one, three, and multiple antibody detection chip subunits, respectively.

[0043] Reference numerals

[0044] 1 is quality control point 1, 2 is quality control point 2, 3 is quality control point 3, 4 is blank control point, 5 is type A foot-and-mouth disease virus antigen detection point, and 6 is type O foot-and-mouth disease virus antigen detection point. DETAILED DESCRIPTION

[0045] definition

[0046] The term "goat anti-mouse polyclonal antibody" is used interchangeably with goat anti-mouse secondary antibody and goat anti-mouse IgG antibody.

[0047] The term "enzyme" includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, and β-D-galactosidase. The substrate used by horseradish peroxidase is o-phenylenediamine (OPD) and tetramethylbenzidine (TMB), preferably tetramethylbenzidine (TMB); the substrate used by alkaline phosphatase is p-nitrophenyl phosphate (p-NPP); the substrate used by β-D-galactosidase is 4-methylumbelliferyl-β-D-galactoside (4MUG).

[0048] The term "virus-like particles" refers to virus-like particles (VLPs) that can be packaged into a virus shell structure when expressed in vitro and / or in vivo. They are pseudoviruses with a similar shell structure to viruses but without the ability to replicate viruses. They do not contain viral nucleic acids and are usually composed of viral capsid proteins or variants or fragments thereof. Since VLPs are very similar in structure to natural virus particles, they have strong immunogenicity and immunoreactivity. At the same time, since VLPs do not contain viral genetic material and have no infectious ability, they have high biosafety.

[0049] The term "goat anti-mouse polyclonal antibody" refers to goat anti-mouse polyclonal antibody, also known as goat anti-mouse secondary antibody or goat anti-mouse IgG.

[0050] The term "heavy chain variable region" refers to a polypeptide having a length of 110 to 125 amino acids, and its amino acid sequence corresponds to the heavy chain amino acid sequence of the monoclonal antibody of the present invention starting from the heavy chain N-terminal amino acid. Similarly, the term "light chain variable region" refers to a polypeptide having a length of 95 to 115 amino acids, and its amino acid sequence corresponds to the light chain amino acid sequence of the monoclonal antibody of the present invention starting from the light chain N-terminal amino acid. It is obvious to a person of ordinary skill in the art that, based on the amino acid sequences of the heavy chain variable region and light chain variable region of the monoclonal antibody specifically disclosed in the present invention, one or more amino acids can be added, deleted, replaced, etc. by conventional genetic engineering and protein engineering methods to obtain conservative variants, while still being able to maintain specific binding to feline panleukopenia virus. The monoclonal antibodies in the present invention also include active fragments or conservative variants thereof.

[0051] The term "microarray chip" refers to a micro device that is arranged in an array on a substrate and can process and analyze biological or chemical information in a sample in parallel. The dot array has a dot diameter of less than 500 μm, and the minimum distance between the centers of two adjacent dots is such that no signal crossover occurs (see GB / T 27990-2011 "Basic Terms of Biochips").

[0052] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0053] Unless otherwise specified, the phosphate buffer used in the embodiments of the present invention is PBS with a pH value of 7.4, and its 1L volume formula is: NaCl 8.0g, KCl 0.2g, Na2HPO4·12H2O 2.9g, KH2PO4 0.24g, but this embodiment does not constitute a limitation of the present invention under any circumstances. Sheep anti-mouse polyclonal antibodies can be obtained commercially or prepared by conventional methods.

[0054] The experimental methods described in the present invention are all conventional methods unless otherwise specified; the biological materials described can be obtained from commercial channels unless otherwise specified.

[0055] Example 1 Preparation of raw materials for the dual detection kit for foot-and-mouth disease virus type O and type A antibodies

[0056] 1.1 Antigen

[0057] Type A foot-and-mouth disease virus antigen: Type A foot-and-mouth disease virus-like particles. For details on the preparation and identification methods, please refer to Chinese patent CN105566449A.

[0058] O-type foot-and-mouth disease virus antigen: O-type foot-and-mouth disease virus-like particles, the preparation and identification methods are detailed in Chinese patent CN105566449A.

[0059] 1.2 Antibodies

[0060] Type A foot-and-mouth disease virus monoclonal antibodies: 2E11 (the nucleotide sequence of its heavy chain variable region is SEQ ID No.1, and the nucleotide sequence of its heavy chain variable region is SEQ ID No.2), 3B4 (the nucleotide sequence of its heavy chain variable region is SEQ ID No.3, and the nucleotide sequence of its heavy chain variable region is SEQ ID No.4).

[0061] O-type foot-and-mouth disease virus monoclonal antibodies: 6G6 (the nucleotide sequence of its heavy chain variable region is SEQ ID No.5, and the nucleotide sequence of its heavy chain variable region is SEQ ID No.6), 7D2 (the nucleotide sequence of its heavy chain variable region is SEQ ID No.7, and the nucleotide sequence of its heavy chain variable region is SEQ ID No.8).

[0062] Quality control: goat anti-mouse polyclonal antibody.

[0063] 1.3 Preparation and identification of enzyme-labeled antibodies

[0064] 1.3.1 Preparation

[0065] The modified sodium periodate method was used to label the monoclonal antibodies 2E11 and 3B4 against type A foot-and-mouth disease virus and 6G6 and 7D2 against type O foot-and-mouth disease virus with horseradish peroxidase (HRP).

[0066] Weigh 20 mg horseradish peroxidase (HRP) and dissolve it in 1 ml ultrapure water, add 1 ml freshly prepared NaIO4 solution (30 mg NaIO4 dissolved in 1 ml ultrapure water), mix well, and incubate at 4°C in the dark for 30 minutes; add 40 μl ethylene glycol to the above solution and incubate at 4°C in the dark for 30 minutes; according to the ratio of 1 mg purified monoclonal antibody to 100 μl of the above mixture, mix the two well, add them to the dialysis bag, mix well, and dialyze with CB buffer for 6 hours. The whole operation needs to be carried out in the dark; transfer the dialyzed mixture to a 1.5 ml EP tube, add 10 μl freshly prepared NaBH4 solution (20 mg NaBH4 dissolved in 1 ml ultrapure water), incubate at room temperature for 2 hours, and mix every 30 minutes; add an equal volume of saturated ammonium sulfate, mix well, and incubate at 4°C for 15 minutes. Centrifuge at 12,000 rpm for 10 minutes and discard the supernatant. The precipitate was suspended by blowing with a mixture of PBS and glycerol (V:V=1:1) having an equal volume to that of the purified antibody.

[0067] 1.3.2 Identification

[0068] Appearance: At room temperature, it is a reddish brown liquid with no flocculent precipitation.

[0069] Quality evaluation: Use a UV spectrophotometer to detect the absorbance value A of the enzyme-labeled antibody at 403nm and 280nm. Calculate the corresponding enzyme parameters according to the formula:

[0070] Enzyme amount (mg / ml) = A 403nm ×0.4×dilution factor.

[0071] IgG amount (mg / ml) = (A 280nm -A 403nm ×0.3)×0.62×dilution factor.

[0072] Molecular ratio (E / P) = enzyme amount × 4 / IgG amount.

[0073] Marking rate = A 403nm / A 280nm .

[0074] After absorbance detection and calculation, the specific results are shown in Table 1:

[0075] Table 1 Quality evaluation of different enzyme-labeled antibodies

[0076]

[0077] Example 2 Preparation of a dual test kit for foot-and-mouth disease virus type O and type A antibodies

[0078] 2.1 Preparation of spotting solution

[0079] Preparation of 5% glycerol solution: accurately weigh 5.00g glycerol and place it in a 100ml volumetric flask, add a small amount of purified water and gently rotate it to dissolve it completely, avoiding excessive bubbles, then add purified water to the scale line, turn it upside down and shake it 10 times, and set aside;

[0080] Preparation of 5% sorbitol solution: accurately weigh 5.00g of sorbitol and place it in a 250ml beaker, add appropriate amount of purified water and stir to completely dissolve it, then transfer it completely to a 100ml volumetric flask, add purified water to the scale line, shake it upside down 10 times, and set aside;

[0081] Preparation of 0.05% Triton solution: Use a pipette to measure 50 μl of Triton into a 100 ml volumetric flask, add an appropriate amount of purified water to completely dissolve it, then add purified water to the scale mark, shake it upside down 10 times, and set aside;

[0082] DMSO solution: Use DMSO reagent directly;

[0083] Preparation of PBS (pH 6.8) solution: first prepare 0.2 mol / L disodium hydrogen phosphate solution and 0.3 mol / L sodium dihydrogen phosphate solution, and then mix the two in a volume ratio of 49:51 to obtain a phosphate buffer solution with a pH value of 6.8;

[0084] The above solutions were mixed evenly in a volume ratio of 10:15:0.1:50:100 to prepare the spotting solution.

[0085] 2.2 Preparation of the combined test kit

[0086] Foot-and-mouth disease virus type O and type A antibody dual detection chip: dilute the type O foot-and-mouth disease virus antigen prepared in Example 1 to an appropriate concentration with the spotting solution prepared in Example 2.1, as the detection point FMDV O spotting solution; dilute the type A foot-and-mouth disease virus antigen prepared in Example 1 to an appropriate concentration with the spotting solution prepared in Example 2.1, as the detection point FMDV A spotting solution; dilute the goat anti-mouse polyclonal antibody to 100 μg / ml, 200 μg / ml, and 300 μg / ml with the spotting solution, as the quality control point spotting solution, and spot on Figure 1The three concentrations are set at points 1, 2, and 3 to facilitate the selection of the corresponding quality control points for data statistical analysis according to the debugging results; the spotting solution prepared in Example 2.1 is used as the blank control spotting solution and is spotted at point 4. The spotting instrument is turned on, the program and spotting parameters are set, and the spotting volume is 20 nL / point. The detection point FMDV A spotting solution is spotted at point 5, the detection point FMDV O spotting solution is spotted at point 6, and the quality control point spotting solution is spotted at Figure 1 The sample solution was spotted at points 1, 2, 3 and blank control in Figure 1 4 in the middle. Take out the spotted membrane and place it in the middle of the chip bottom plate, add the cover plate to press it tightly, fix the edge strips on both sides, assemble it into a foot-and-mouth disease virus type O and type A antibody dual detection detection chip, package it, and store it at 2-8°C. Except that points 1, 2, 3, and 4 are fixed at the upper left corner, lower left corner, lower right corner, and upper right corner of the detection chip, respectively, points 5 and 6 can be spotted at any other position of the detection chip, as long as the distance from the edge of other points is ≥700μm, and the shortest distance between any points is also ≥700μm. The distance from quality control point 1, quality control point 2, quality control point 3, and blank control spot point 4 to the upper and lower edges of the detection chip subunit is ≥8mm, and the distance to the left and right edges of the detection chip subunit is ≥5mm.

[0087] The antibody joint test kit includes one or more foot-and-mouth disease virus type O and type A antibody dual joint test detection chip subunits, which are composed of a bottom end, an upper grid, and an independent detection hole composed of a detection chip arranged therebetween and clamped by the bottom end and the upper grid. Each detection hole corresponds to one detection chip subunit. When the antibody joint test kit includes multiple foot-and-mouth disease virus type O and type A antibody dual joint test detection chip subunits, each of the independent detection chip subunits is integrated into a microarray chip. Figure 2 The kit with different numbers of foot-and-mouth disease virus type O and type A antibody dual detection chip subunits is shown. Figure 2 O, P, and Q in the middle are test kits with one, three, and multiple antibody detection chip subunits, respectively, and the partial enlarged image thereof shows the spotting points on the detection chip in a foot-and-mouth disease virus type O and type A antibody dual detection detection chip subunit.

[0088] Enzyme labeling reagent: PBS solution and 200 ml of fetal bovine serum were mixed and supplemented with PBS to a volume of 1 L as enzyme labeling diluent. The enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibodies 2E11 and 3B4 and O-type foot-and-mouth disease virus monoclonal antibodies 6G6 and 7D2 prepared in Example 1 were diluted with the enzyme labeling diluent according to the final volumes of enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibodies and enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibodies of 0.0025% V / V and 0.005% V / V, respectively, and then mixed (the concentrations of A-type and O-type enzyme-labeled monoclonal antibodies were 75 ng / ml and 100 ng / ml, respectively), filtered at 0.22 μm, and aseptically packaged.

[0089] Sample diluent: PBS solution containing 10% V / V fetal bovine serum, 0.05%-0.2% V / V Triton-100, and 0.1% V / V Proclin300.

[0090] Washing solution: PBS solution containing 1% V / V Tween 20, filtered through 0.22 μm, and sterilely packaged. Dilute 20 times with purified water for detection.

[0091] Substrate solution: TMB (3,3',5,5'-tetramethylbenzidine) solution, commercial product, sterile packaging.

[0092] 2.3 Detection method establishment

[0093] The steps are as follows:

[0094] (1) Sample pre-dilution: dilute the serum sample 10 times with sample diluent (e.g. 10 μl sample + 90 μl sample diluent).

[0095] (2) Numbering: Number the chip holes according to the sample sequence.

[0096] (3) Infiltration: Add 300 μl / well of washing solution, infiltrate for 3 minutes, then discard the solution and pat dry.

[0097] (4) Add 50-100 μl / well of the diluted sample and incubate the microplate in a thermostatic oscillator at 37°C and 500 rpm for 30 min.

[0098] (5) Add enzyme labeling reagent, add 50-100 μl / well, place the microplate in a constant temperature oscillator at 37°C and 500 rpm for 30 minutes; discard the liquid, add 300 μl / well of washing solution, soak for 10-20 seconds, and discard the liquid. Repeat the washing for 5 times, and pat dry for the last time.

[0099] (6) Color development: Add 100 μl / well of substrate solution and incubate at 37°C for 15 min.

[0100] (7) Determination: vertically discard the liquid, shake off, remove the chip cover, turn it upside down on a dust-free paper, gently press dry, and measure the result with a microplate chip imager within 10 minutes to derive the blocking rate (1-sample S value / quality control point N value).

[0101] Test validity determination: The gray value of the quality control point should be ≥10000, and the gray value of the blank control point should be ≤3000, otherwise the test is invalid. This determination is completed automatically by the internal data processing and analysis system. The results determination (this determination is also completed automatically by the internal one-key intelligent data processing and analysis system, and no technical personnel are required to perform data calculations and statistical analysis) standards are as follows:

[0102] Calculation of blocking rate: blocking rate = (1-sample gray value / quality control point gray value) × 100%

[0103] Positive determination: FMDV O and A antibodies are positive when the blocking rate is ≥50%;

[0104] Negative determination: When the blocking rate is less than 50%, FMDV O and A antibodies are negative.

[0105] For ease of explanation, this kit is introduced using 75 μl / well sample volume as an example.

[0106] 2.4 Determination of antigen coating amount of foot-and-mouth disease virus type O and type A antibody dual detection chip

[0107] The serum samples were as follows:

[0108] Pig serum with positive FMDV O antibody and negative FMDV A antibody (referred to as P1): the result of the test using the Lanzhou Veterinary Institute's foot-and-mouth disease virus type O antibody liquid phase blocking ELISA detection kit was positive, with an antibody titer of 1:360; and the result of the test using the Lanzhou Veterinary Institute's foot-and-mouth disease virus type A antibody liquid phase blocking ELISA detection kit was negative, with an antibody titer of 1:16.

[0109] Pig serum with positive FMDV A antibody and negative FMDV O antibody (referred to as P2): the result of the test using the Lanzhou Veterinary Institute's foot-and-mouth disease virus type A antibody liquid phase blocking ELISA detection kit was positive, with an antibody titer of 1:256; and the result of the test using the Lanzhou Veterinary Institute's foot-and-mouth disease virus type O antibody liquid phase blocking ELISA detection kit was negative, with an antibody titer of 1:8.

[0110] Pig serum with negative FMDV O antibody and negative FMDV A antibody (abbreviated as N): The results of the test using the Lanzhou Veterinary Research Institute's foot-and-mouth disease virus type O antibody liquid phase blocking ELISA detection kit and the Lanzhou Veterinary Research Institute's foot-and-mouth disease virus type A antibody liquid phase blocking ELISA detection kit were both negative, and the antibody titers were both 1:8.

[0111] The above serum was used to select the antigen coating amount of the foot-and-mouth disease virus type O and type A antibody dual test chip. Since the principle of this method is enzyme-linked immunosorbent solid phase competition, the N / P value was calculated and the antigen coating condition corresponding to the maximum N / P value was selected as the optimal antigen solid phase condition for screening. The details are as follows:

[0112] 2.4.1 Selection of coating amount of O-type foot-and-mouth disease virus antigen

[0113] According to Example 2.1, the O-type foot-and-mouth disease virus antigen of Example 1 was diluted to an appropriate concentration with the spotting solution, and the spotting volume was 20 nl, so that the final coating amount of the O-type foot-and-mouth disease virus antigen spotted on the membrane was as shown in Table 2, and the others remained unchanged. The P1 and N sera were used to detect according to the method of Example 2.3, and the results (see Table 2) were as follows: the detection was negative when the coating amount of the A-type foot-and-mouth disease virus antigen remained unchanged (not shown in Table 2); N / P1 was small when the coating amount of the O-type foot-and-mouth disease virus antigen was low, and increased with the increase of the coating concentration. When the coating amount was 8-32 ng / point, the N / P value was greater than 2.9, and then the N / P1 value began to decrease when the coating concentration was increased. The size of the N / P1 value corresponds to the ability of the method to distinguish between negative and positive. The larger the data, the more suitable the detection conditions. Therefore, when the coating amount of O-type foot-and-mouth disease virus antigen is 1-128 ng / point, the N / P1 value is 2.33-3.32, which can meet the detection requirements. However, when the coating amount is 8-32 ng / point, the N / P1 value is slightly better (2.97-3.32), and when the coating amount is 16 ng / point, the N / P1 value is the optimal (3.32).

[0114] Table 2 Optimization results of O-type foot-and-mouth disease virus antigen coating amount

[0115]

[0116] 2.4.2 Selection of coating amount of FMDV type A antigen

[0117] According to Example 2.1, the A-type foot-and-mouth disease virus antigen of Example 1 was diluted to an appropriate concentration with the spotting solution, and the spotting volume was 20 nl, so that the final coating amount of the A-type foot-and-mouth disease virus antigen spotted on the membrane was as shown in Table 3, and the others remained unchanged. The detection was carried out using P2 and N serum according to the method of Example 2.3, and the results (see Table 3) were as follows: the detection was negative when the coating amount of the O-type foot-and-mouth disease virus antigen remained unchanged (not shown in Table 3); N / P2 was small when the coating amount of the A-type foot-and-mouth disease virus antigen was low, and increased with the increase of the coating concentration. When the coating amount was 16-64 ng / point, the N / P2 value was greater than 3.1, and then the N / P2 value began to decrease when the coating concentration was increased. The size of the N / P2 value corresponds to the ability of the method to distinguish between negative and positive. The larger the data, the more suitable the detection conditions. Therefore, when the coating amount of type A foot-and-mouth disease virus antigen is 1-128 ng / point, the N / P2 value is 2.08-3.45, which can meet the detection requirements. However, when the coating amount is 16-64 ng / point, the N / P2 value is slightly better (3.14-3.45), and when the coating amount is 32 ng / point, the N / P2 value is the optimal value (3.45).

[0118] Table 3 Optimization results of the coating amount of type A foot-and-mouth disease virus antigen

[0119]

[0120] 2.4.3 Verification of the amount of O-type and A-type foot-and-mouth disease virus antigen coating

[0121] In order to verify whether there is a cross reaction between O-type and A-type foot-and-mouth disease virus antigens when detecting corresponding antibodies, samples with clear background and tested by commercial kits were selected to further verify the coating amount of O-type and A-type foot-and-mouth disease virus antigens. According to the above test results, O-type foot-and-mouth disease virus antigen was spotted at 16ng / spot and A-type foot-and-mouth disease virus antigen was spotted at 32ng / spot to prepare a dual detection chip for foot-and-mouth disease virus O-type and A-type antibodies. And 3 sera after immunization with foot-and-mouth disease virus O-type subunit vaccine, 3 sera after immunization with foot-and-mouth disease virus A-type subunit vaccine, and 6 sera for specific testing (including 1 PCV2 positive serum, 1 CSFV positive serum, 1 PPV positive serum, 1 PRRSV positive serum, 1 healthy pig serum, and 1 PRV positive serum), a total of 12 samples were tested separately, and the results were in accordance with the standard for 12 / 12, that is, the corresponding coating amount when the compliance rate was 100% was the optimal coating amount. Results (see Table 4): The results of the prepared foot-and-mouth disease virus type O and type A antibody dual detection chip for testing 12 samples were consistent with those of the commercial kit, with a compliance rate of 100%.

[0122] Table 4 Evaluation results of the optimal antigen coating amount for preparing the foot-and-mouth disease virus type O and type A antibody dual detection detection chip and comparison with commercial kits

[0123]

[0124] 2.5 Selection of enzyme-labeled monoclonal antibodies against type O foot-and-mouth disease virus

[0125] The O-type and A-type foot-and-mouth disease virus antibody dual detection chip prepared in 2.4.3 was used to dilute the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibodies 6G6 and 7D2 in Example 1 to 100 ng / ml (1:20000). The P1 and N sera were used to perform the test according to the method in Example 2.3. The results (see Table 5) showed that the N / P1 results of the two enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody solutions were better than those of 6G6 in the 7D2 test, indicating that the monoclonal antibody 7D2 had a greater advantage in recognizing the epitope of the O-type foot-and-mouth disease virus than the epitope recognized by 6G6. In subsequent experiments, the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 was used to produce the kit.

[0126] Table 5 Results of enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody selection

[0127] Labeled monoclonal antibody 6G6 7D2 N 36512 38129 P1 10245 6891 N / P1 3.56 5.53

[0128] 2.6 Selection of enzyme-labeled monoclonal antibodies to foot-and-mouth disease virus type A

[0129] Using the foot-and-mouth disease virus type O and type A antibody dual detection chip prepared in 2.4.3, the enzyme-labeled type A foot-and-mouth disease virus monoclonal antibodies 2E11 and 3B4 of Example 1 were diluted to 75ng / ml (1:40000). The detection was performed using P2 and N sera according to the method of Example 2.3. The results (see Table 6) showed that the N / P2 results of the two enzyme-labeled type A foot-and-mouth disease virus monoclonal antibody solutions were better than those of 2E11 in the detection of 3B4, indicating that the monoclonal antibody 3B4 has a greater advantage in recognizing the epitope of type A foot-and-mouth disease virus than the epitope recognized by 2E11. Subsequent experiments will use the enzyme-labeled type A foot-and-mouth disease virus monoclonal antibody 3B4 to produce a kit.

[0130] Table 6 Results of enzyme-labeled monoclonal antibody selection for type A foot-and-mouth disease virus

[0131] Labeled monoclonal antibody 2E11 3B4 N 32516 33813 P2 10813 7917 N / P2 3.01 4.27

[0132] 2.7 Selection of sample diluent

[0133] The foot-and-mouth disease virus type O and type A antibody dual detection chip and enzyme-labeled reagent were used together with the sample diluent prepared in Table 7 to test the N, P1, and P2 samples. The results (see Table 7) were as follows: After the samples were treated with the seven sample treatment solutions, the values ​​of N / P1 and N / P2 detected after the samples were treated with sample diluent 4 were the largest, and the effect was the best.

[0134] Table 7 Test results of different sample dilutions

[0135]

[0136]

[0137] In order to evaluate the content of Triton-100 in the sample diluent, other components were kept unchanged, and the content of Triton-100 was adjusted to 0.025%, 0.05%, 0.1%, 0.2%, 0.4%, and 0.8% V / V to prepare sample diluents and conduct detection. The results showed that when the Triton-100 contained in the sample processing solution was 0.025%, the sensitivity of detecting FMDV O and A antibodies decreased by 20 to 60 times; when the Triton-100 contained in the sample processing solution was 0.4% and 0.8%, the specificity of detecting FMDV O and A antibodies was poor; and when the Triton-100 content in the sample processing solution was 0.05% and 0.2%, the detection sensitivity and specificity of the sample diluent prepared were equivalent to the results of sample diluent 4, so the content of Triton-100 in the sample diluent was set to 0.05% to 0.2% V / V.

[0138] To facilitate subsequent evaluation, a dual detection chip for foot-and-mouth disease virus type O and type A antibodies (FMDV O coating amount 16 ng / spot, FMDV A coating amount 32 ng / spot), enzyme-labeled reagent (enzyme-labeled type O foot-and-mouth disease virus monoclonal antibody 7D2, enzyme-labeled type A foot-and-mouth disease virus monoclonal antibody 3B4, the final volume of which was a mixture diluted 1:20000 and 1:40000, respectively), sample diluent 4 (PBS solution containing 10% V / V fetal bovine serum, 0.1% V / V Triton-100, and 0.1% V / V Proclin300), together with substrate solution and washing solution were used to prepare a kit for subsequent detection.

[0139] Example 3 Application of the joint test kit

[0140] 3.1 Sensitivity

[0141] Southeast Asian O-type foot-and-mouth disease virus antibody-positive serum (the antibody titer was 1:5760 calibrated by the OIE recommended method) was diluted 2 times in a gradient manner and measured using the foot-and-mouth disease virus O-type and A-type antibody dual detection kit prepared by the present invention to determine the sensitivity of the kit to Southeast Asian O-type positive serum. The results are shown in Table 8.

[0142] Table 8 Sensitivity test for serial dilution of Southeast Asian O-type positive serum

[0143] Dilution multiple Blocking rate (%) Result determination 1∶8 98.1 + 1∶16 96.2 + 1∶32 91.3 + 1∶64 85.1 + 1∶128 76.8 + 1∶256 61.2 + 1∶512 42.5 -

[0144] The results showed that the test kit could detect gradiently diluted Southeast Asian O-type positive serum with a detection titer of 1:256.

[0145] The positive serum of Chinese type O foot-and-mouth disease virus antibody (the antibody titer was 1:5760 calibrated by the OIE recommended method) was diluted 2 times in a gradient manner and measured using the foot-and-mouth disease virus type O and type A antibody dual detection kit prepared by the present invention to determine the sensitivity of the kit to Chinese type O positive serum. The results are shown in Table 9.

[0146] Table 9 Sensitivity test for gradient dilution of Chinese type O positive serum

[0147]

[0148]

[0149] The results showed that the test kit could detect gradiently diluted Southeast Asian O-type positive serum with a detection titer of 1:256.

[0150] The positive serum for type A foot-and-mouth disease virus antibody (the antibody titer was 1:2880 calibrated by the OIE recommended method) was diluted 2 times in a gradient manner and measured using the foot-and-mouth disease virus type O and type A antibody dual detection kit prepared by the present invention to determine the sensitivity of the kit to positive serum. The results are shown in Table 10.

[0151] Table 10 Sensitivity test for type A positive serum with gradient dilution

[0152] Dilution multiple Blocking rate (%) Result determination 1∶8 96.1 + 1∶16 94.3 + 1∶32 85.6 + 1∶64 72.9 + 1∶128 53.7 + 1∶256 36.8 -

[0153] The results showed that the test kit could detect gradiently diluted type A positive serum with a detection titer of 1:128.

[0154] The above results show that the foot-and-mouth disease virus type O and type A antibody dual detection kit of the present invention has high sensitivity. It can not only perform high-sensitivity detection of foot-and-mouth disease virus type O and type A antibodies, but also perform high-sensitivity detection of foot-and-mouth disease virus type O antibodies of different subtypes (Southeast Asian type, Chinese type) with high sensitivity.

[0155] 3.2 Specificity

[0156] The foot-and-mouth disease virus O type and A type antibody dual test kit prepared by the present invention was used to test 3 FMDV O type antibody positive sera (A type negative), 3 FMDV A type antibody positive sera (O type negative), 3 foot-and-mouth disease O type and A type antibody negative sera, 1 classical swine fever virus (CSFV) antibody positive serum, 1 porcine reproductive and respiratory syndrome virus (PRRSV) antibody positive serum, 1 porcine Seneca virus (SVV) antibody positive serum and 1 Escherichia coli (E.coli) antibody positive serum to evaluate its specificity. The results are shown in Table 11.

[0157] Table 11 Specificity evaluation results

[0158]

[0159] The results showed that the kit detected three FMDV O antibody-positive sera, and all O-type antibodies were positive, while all A-type antibodies were negative; detected three FMDV A antibody-positive sera, and all A-type antibodies were positive, while all O-type antibodies were negative; detected three FMDV negative sera, and all O and A antibodies were negative; indicating that the kit detected no cross-reaction between O and A antibodies, and had good specificity. The kit detected other swine disease virus antibody-positive sera, and all O and A antibodies were negative, indicating that the kit had no cross-reaction with other virus antibodies, and had good specificity.

[0160] 3.3 Repeatability

[0161] Using chip boards from three different batches, intra-batch repeatability tests were performed on one board, and inter-batch repeatability tests were performed on boards from three different batches. The grayscale value and blocking rate were measured, and the coefficient of variation was calculated. The coefficient of variation was <15%, indicating that the kit had good repeatability and stability. The results showed that the intra-batch and inter-batch test results of the chip boards from three different batches were consistent, and the coefficient of variation was <10%, indicating that the kit had good repeatability.

[0162] The coefficient of variation (CV) calculation formula is:

[0163] CV (%) = (standard deviation / mean value) × 100%

[0164] 3.3 Clinical application

[0165] 191 sera that were positive for Southeast Asian O-type foot-and-mouth disease and negative for A-type foot-and-mouth disease (calibrated by the OIE recommended method) were tested by three batches of the foot-and-mouth disease virus O-type and A-type antibody dual detection kit prepared by the present invention and three batches of commercial liquid phase blocking kits. The results are shown in Table 12.

[0166] Table 12 Comparison test results of the kit for Southeast Asian O-type foot-and-mouth disease detection

[0167]

[0168] The results showed that the three batches of the kit of the present invention were able to detect 100% of the positive Southeast Asian O-type foot-and-mouth disease antibodies, while the three batches of the commercial liquid phase blocking kit had different detection results, with the lowest being 96.3% and the highest being 97.9%. Not only was the sensitivity low, but there were also differences between batches.

[0169] 172 sera that were positive for Chinese type O foot-and-mouth disease and negative for type A foot-and-mouth disease (calibrated by the OIE recommended method) were tested by three batches of the foot-and-mouth disease virus type O and type A antibody dual detection kit prepared by the present invention and three batches of commercial liquid phase blocking kits. The results are shown in Table 13.

[0170] Table 13 Comparison test results of the kit for Chinese type O foot-and-mouth disease detection

[0171]

[0172] The results showed that the three batches of the kit of the present invention could detect 100% of the positive antibodies of Chinese type O foot-and-mouth disease, while the three batches of the commercial liquid phase blocking kit had different detection results, with the lowest being 94.2% and the highest being 97.7%. Not only was the sensitivity low, but there were also differences between batches.

[0173] 183 sera that were positive for type A foot-and-mouth disease and negative for type O foot-and-mouth disease (calibrated by the OIE recommended method) were tested by three batches of the foot-and-mouth disease virus type O and type A antibody dual detection kit prepared by the present invention and three batches of commercial liquid phase blocking kits. The results are shown in Table 14.

[0174] Table 14 Comparison test results of kit for type A foot-and-mouth disease detection

[0175]

[0176]

[0177] The results showed that the three batches of the kit of the present invention could detect 100% of the positive type A foot-and-mouth disease antibodies, while the three batches of the liquid phase blocking kit had different detection results, with the lowest being 93.4% and the highest being 97.8%. Not only was the sensitivity low, but there were also differences between batches.

[0178] 149 sera (89 of which were Southeast Asian O type and 60 of which were Chinese O type) that were positive for both foot-and-mouth disease O type and A type (calibrated by the OIE recommended method) were tested by comparison using three batches of the foot-and-mouth disease virus O type and A type antibody dual detection kit prepared by the present invention and three batches of commercial liquid phase blocking kits. The results are shown in Table 15.

[0179] Table 15 Comparison test results of the kit for foot-and-mouth disease O type and A type positive samples

[0180]

[0181] The results showed that the three batches of the kit of the present invention detected 100% positive results for O-type and A-type antibodies in negative serum of foot-and-mouth disease, with good specificity, while the three batches of commercial liquid phase blocking kits had detection results lower than 100% and there were differences between batches.

[0182] 151 sera that were negative for both type O and type A of foot-and-mouth disease (calibrated by the OIE recommended method) were tested by three batches of the foot-and-mouth disease virus type O and type A antibody dual test kit prepared by the present invention and three batches of commercial liquid phase blocking kits. The results are shown in Table 16.

[0183] Table 16 Comparison test results of the kit for foot-and-mouth disease type O and type A negative samples

[0184]

[0185] The results showed that the three batches of the kit of the present invention detected 100% negative results for O-type and A-type antibodies of negative foot-and-mouth disease serum, with good specificity, while the three batches of commercial liquid phase blocking kits had unstable test results and some were less than 100%.

[0186] In summary, the foot-and-mouth disease virus type O and type A antibody dual detection kit of the present invention has good detection capabilities for antibodies of different genetic topology types, and can also better solve the problems of large batch differences and poor stability of current liquid phase blocking ELISA kits.

[0187] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes using the technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the scope of the technical solution of the present invention. SEQUENCE LISTING <110> Luoyang Zhongke Biochip Technology Co., Ltd. <120> A foot-and-mouth disease virus O type and A type antibody joint detection kit and its preparation method and application <160> 8 <170> PatentIn version 3.3 <210> 1 <211> 345 <212> DNA <213> Hybridoma <400> 1 caggtccaac ttcagcagcc tggggctgaa ctggtgaaat ctgggacttc agtgaaaatg 60 tcctgcaagg cttctggcta caccttcacc agttatactgga ttcactgggt gaagcagagg 120 ccgggacaag gccttgagtg gattggagat atttttccta ctagtgatag tattaactac 180 aatgagaagt tcaagaccaa ggccacactg actgtagaca catcctccag tacagcctac 240 atgcaactca gcagcctgac atctgaggac tctgcggtct attattgtgc cattcttcta 300 tccgtgggct actggggcca aggcaccact ctcacagtct cctca 345 <210> 2 <211> 340 <212> DNA <213> Hybridoma <400> 2 gacattgtga tgacacagtt tccatcctcc ctgaccgtga cagcaggaga gaaggtcact 60 atgagctgca agtccagtca gagtctgtta aacagtggaa atcaaaagaa cttcttgacc 120 tggtaccagc agaagtcagg gcagccccct aaactgttga tctactgggc atccactagg 180 gaatctgggg tccctgatcg cttcataggc agtggatcca gaacagattt cactctcacc 240 atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga ttataattat 300 ccgctcacgt tcggtgctgg gaccaagctg gagctgaaac 340 <210> 3 <211> 354 <212> DNA <213> Hybridoma <400> 3 caggtccaac tgcagcaacc tgggtctgag ctggtgaggc ctggagcttc agtgaagctg 60 tcctgcaagg cttctggcta cacattcacc agctactgga tgcactgggt gaagcagagg 120 cctggacaag gccttgagtg gattggaaat atttatcctg atagtggtag ttttaattac 180 gatgagaaat tcaagagcaa ggccacactg actgtagaca catcctccag cacagcctac 240 atgcagctca gcagcctgac atctgaggac tctgcggtct attattgtac aagagtccac 300 tataggcacg ggtttgctta ctggggccaa gggactctgg tcactgtctc tgca 354 <210> 4 <211> 306 <212> DNA <213> Hybridoma cells <400> 4 caaattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gagggtcacc 60 atgacctgca gtgccagctc aggtgtaagt tacatgtact ggtatcagca gaagccagga 120 tcctccccca gactcctgat ttatgccaca tccaacttgg cttctggagt ccctgttcgc 180 ttcagtggca gtgggtctgg gacctcttac tctctcacaa tcagccgaat ggaggctgaa 240 gatgctgcca cttattactg ccagcagtgg acttattacc cgttcacgtt cggagggggg 300 accgag 306 <210> 5 <211> 378 <212> DNA <213> Hybridoma cell <400> 5 gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggggcttc agtgaagata 60 tcctgcaaga cttctggata cacattcact gaatacacca tgcactgggt gaagcagagc 120 catggaaaga gccttgagtg gattggaggt attaatccta acaatggtgt tcctagttac 180 aaccagaagt tcaagggcaa ggccacattg actgtagaca agtcctccag cacaccctac 240 atggacctcc gcagcctgac atctgaggat tctgcagtct attactgtgt aagaaaagga 300 tactataggt acgacgtaga gacgtcgggg tttgctatgg actactgggg tcaaggaacc 360 tcagtcaccg tctcctca 378 <210> 6 <211> 342 <212> DNA <213> Hybridoma cell <400> 6 gacattgtga tgtcacagtc tccatcctcc ctagctgtgt cagttggaga gaaggttact 60 gtgagctgca ggtccagtca gagcctttta tatagtagca atcaaaagaa ctacttggcc 120 tggtaccagc agaaaccagg gcagtctcct aaactgctga tttactgggc atccactagg 180 gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 240 atcagcagtg tgaaggctga agacctggca gtttattact gtcagcaata ttatagctat 300 ccgtacacgt tcggaggggg gaccaagctg gaaataaaac gg 342 <210> 7 <211> 354 <212> DNA <213> Hybridoma <400> 7 caggtccaac tgcagcaacc tgggtctgag ctggtgaggc ctggagcttc agtgaagctg 60 tcctgcaagg cttctggcta cacattcacc agctactgga tgcactgggt gaagcagagg 120 cctggacaag gccttgagtg gattggaaat atttatcctg atagtggtag ttttaattac 180 gatgagaaat tcaagagcaa ggccacactg actgtagaca catcctccag cacagcctac 240 atgcagctca gcagcctgac atctgaggac tctgcggtct attattgtac aagagtccac 300 tataggcacg ggtttgctta ctggggccaa gggactctgg tcactgtctc tgca 354 <210> 8 <211> 321 <212> DNA <213> Hybridoma <400> 8 gacattgtga tgacccagtc tcacaaattc atgtccacat your feet cagggtcagc 60 atcacctgca aggccagtca ggatgtgagt actgctgtag tctggtatca agaaacca 120 ggacaatctc ctaaactact aatttactcg gcatccttcc ggtactctgg agtccctgat 180 cgcttcactg gcagtggatc tgggacggat ttcactttca ccatcagcag tgttcaggct 240 gaagacctgg cagtttatta ctgtcagcaa cattatacta ctccgctcac gttcggtgct 300 gggaccaagc tggagctgaa a 321

Claims

1. A combined detection kit for antibodies of foot-and-mouth disease virus type O and type A, wherein: The antibody joint detection kit comprises one or more foot-and-mouth disease virus type O and type A antibody detection chips, and an enzyme-labeled reagent. The spotting points on the foot-and-mouth disease virus type O and type A antibody detection chips are respectively coated with foot-and-mouth disease virus type O antigen, foot-and-mouth disease virus type A antigen, a quality control product, and a blank control; the O-type foot-and-mouth disease virus antigen is an O-type foot-and-mouth disease virus-like particle, the A-type foot-and-mouth disease virus antigen is an A-type foot-and-mouth disease virus-like particle, the quality control product is a sheep anti-mouse polyclonal antibody, the blank control is a spotting solution, the enzyme-labeled reagent is a solution containing an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody and an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody, the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody is an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 or an enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 6G6, the enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody is an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4 or an enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 2E11, The heavy chain variable region of the O-type foot-and-mouth disease virus monoclonal antibody 7D2 is encoded by the sequence shown in SEQ.ID NO.7 or its degenerate sequence, and the light chain variable region is encoded by the sequence shown in SEQ.ID NO.8 or its degenerate sequence; The heavy chain variable region of the O-type foot-and-mouth disease virus monoclonal antibody 6G6 is encoded by the sequence shown in SEQ.ID NO.5 or its degenerate sequence, and the light chain variable region is encoded by the sequence shown in SEQ.ID NO.6 or its degenerate sequence; The heavy chain variable region of the type A foot-and-mouth disease virus monoclonal antibody 3B4 is encoded by the sequence shown in SEQ.ID NO.3 or its degenerate sequence, and the light chain variable region is encoded by the sequence shown in SEQ.ID NO.4 or its degenerate sequence; The heavy chain variable region of the type A foot-and-mouth disease virus monoclonal antibody 2E11 is encoded by the sequence shown in SEQ.ID NO.1 or its degenerate sequence, and the light chain variable region is encoded by the sequence shown in SEQ.ID NO.2 or its degenerate sequence.

2. The antibody joint test kit according to claim 1, wherein: The coating amount of the O-type foot-and-mouth disease virus antigen is 1 to 128 ng / spot; The coating amount of the type A foot-and-mouth disease virus antigen is 1 to 128 ng / spot; The control sample is spotted on control sample spots 1 to 3, the coating amount of control sample spot 1 is greater than or equal to 1 ng / spot and less than 4 ng / spot; the coating amount of control sample spot 2 is 4 ng / spot; the coating amount of control sample spot 3 is greater than 4 ng / spot and less than or equal to 6 ng / spot; The spotting solution is prepared by mixing 5% m / v glycerol solution, 5% m / v sorbitol solution, 0.05% v / v Triton solution, DMSO solution, and PBS solution with a pH of 6.8 in a volume ratio of 10:15:0.1:50:

100.

3. The antibody joint test kit according to claim 2, wherein: The coating amount of the O-type foot-and-mouth disease virus antigen is 8-32 ng / spot.

4. The antibody joint detection kit according to claim 2, wherein: The coating amount of the type A foot-and-mouth disease virus antigen is 16-64 ng / spot.

5. The antibody joint test kit according to claim 2, wherein: The enzyme-labeled reagent is a solution containing enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 and enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4; The buffer used for the enzyme labeling reagent is a PBS solution containing 20% ​​fetal bovine serum by volume, wherein the final concentrations of the enzyme-labeled O-type foot-and-mouth disease virus monoclonal antibody 7D2 and the enzyme-labeled A-type foot-and-mouth disease virus monoclonal antibody 3B4 are 100 ng / ml and 75 ng / ml respectively; the enzyme labeled by the enzyme labeling reagent is horseradish peroxidase, alkaline phosphatase or beta-D-galactosidase.

6. The antibody joint detection kit according to claim 2, wherein: In the foot-and-mouth disease virus type O and type A antibody joint detection kit, the coating amount of the foot-and-mouth disease virus type O antigen is 16 ng / spot, and the coating amount of the foot-and-mouth disease virus type A antigen is 32 ng / spot.

7. The antibody joint test kit according to claim 1, wherein: The kit also includes a sample diluent, a substrate solution, and a washing solution; The sample diluent is a PBS solution containing 10% V / V fetal bovine serum, 0.05% to 0.2% V / V Triton-100, and 0.1% V / V Proclin300; The substrate solution is TMB (3,3',5,5'-tetramethylbenzidine) solution; The washing solution is a PBS solution containing 1% V / V Tween 20.

8. The antibody combined detection kit according to any one of claims 1 to 7, wherein: The coating amount of the sheep anti-mouse polyclonal antibody of the quality control point (1), the quality control point (2), and the quality control point (3) in the detection chip is 2ng / point, 4ng / point, and 6ng / point respectively; the blank control spot (4) is a background detection spot; the foot-and-mouth disease virus type A antigen is spotted at the spot (5); the foot-and-mouth disease virus type O antigen is spotted at the spot (6); the quality control point (1), the quality control point (2), the quality control point (3), and the blank control spot (4) are The sample points are respectively located at the upper left corner, lower left corner, lower right corner and upper right corner of the detection chip, and the points (5) and (6) are respectively located at other positions of the detection chip. The distance between the midpoint of the points (1) to (6) and the edge of the point is ≥700 μm; the distance between the quality control point (1), the quality control point (2), the quality control point (3) and the blank control sample point (4) to the upper edge and lower edge of the detection chip subunit is ≥8 mm, and the distance to the left edge and right edge of the detection chip subunit is ≥5 mm; The antibody joint test kit includes one or more subunits of the foot-and-mouth disease virus type O and type A antibody detection chip, and is composed of a bottom end, an upper grid, and a detection chip arranged therebetween and clamped by the bottom end and the upper grid to form an independent detection hole. One detection hole corresponds to one detection chip subunit. When the antibody joint test kit includes multiple foot-and-mouth disease virus type O and type A antibody detection chip subunits, each of the independent detection chip subunits is integrated into a microarray chip.

9. A method for preparing the antibody joint detection kit for foot-and-mouth disease virus type O and type A according to any one of claims 1 to 8, wherein: The method comprises: Step (1) preparing foot-and-mouth disease virus type O antigen and foot-and-mouth disease virus type A antigen respectively, diluting them with spotting solution together with goat anti-mouse polyclonal antibody, and spotting them on the membrane to prepare antibody detection chips for foot-and-mouth disease virus type O and type A; Step (2) comprises a bottom end, an upper grid, and the antibody detection chip of step (1) disposed therebetween to form an independent detection hole, wherein the antibody detection chip is disposed between the bottom end and the upper grid and clamped by the bottom end and the upper grid, wherein one detection hole corresponds to one detection chip subunit, and when the antibody joint detection kit comprises a plurality of antibody detection chip subunits for foot-and-mouth disease virus type O and type A, each of the independent detection chip subunits is integrated into a microarray chip; Step (3) using enzymes to label the O-type foot-and-mouth disease virus monoclonal antibody 7D2 and the A-type foot-and-mouth disease virus monoclonal antibody 3B4, respectively, and diluting them with enzyme labeling diluent to a final concentration of 100 ng / ml and 75 ng / ml, respectively, and then mixing them to serve as enzyme labeling reagents, wherein the enzyme labeling diluent is a PBS solution containing a final volume of 20% V / V fetal bovine serum; Step (4) preparing a sample diluent, a washing solution, and a substrate solution; and Step (5) assembles the antibody detection chip subunits or subunit microarray chips of foot-and-mouth disease virus type O and type A prepared in step (2), the enzyme-labeled reagent prepared in step (3), and the sample diluent, the washing solution, and the substrate solution prepared in step (4) into the antibody joint detection kit.

10. The method according to claim 9, wherein: The spotting solution in step (1) is a mixture of 5% m / v glycerol solution, 5% m / v sorbitol solution, 0.05% v / v Triton solution, DMSO solution, and pH 6.8 PBS solution in a volume ratio of 10:15:0.1:50:100; the goat anti-mouse polyclonal antibody is diluted to 100 μg / ml, 200 μg / ml, and 300 μg / ml respectively with the spotting solution, and the solution is used as a quality control spotting solution and is spotted at points (1), (2), and (3) respectively; the spotting solution is used as a blank control and is spotted at point (4); the foot-and-mouth disease virus type A antigen is spotted at spotting point (5); and the foot-and-mouth disease virus type O antigen is spotted at spotting point (6); The quality control product point (1), the quality control product point (2), the quality control product point (3), and the blank control point (4) are respectively located at the upper left corner, the lower left corner, the lower right corner, and the upper right corner of the detection chip; the points (5) and (6) are respectively spotted at other positions of the detection chip; the distance between the midpoint of the points (1) to (6) and the edge of the point is ≥700 μm; the distance between the quality control product point (1), the quality control product point (2), the quality control product point (3), and the blank control point (4) and the upper edge and lower edge of the detection chip subunit is ≥8 mm, and the distance to the left edge and right edge of the detection chip subunit is ≥5 mm; The enzyme-labeled diluent in step (3) is a PBS solution containing 20% ​​V / V fetal bovine serum; The sample diluent in step (4) is a PBS solution containing 10% V / V fetal bovine serum, 0.05% to 0.2% V / V Triton-100, and 0.1% V / V Proclin300; The washing solution is a PBS solution containing 1% V / V Tween 20, and the substrate solution is a TMB (3,3',5,5'-tetramethylbenzidine) solution.

11. Use of the antibody joint detection kit according to any one of claims 1 to 8 in the preparation of non-immune diagnosis.

12. The use according to claim 11, wherein: The applications of the non-immune diagnosis include epidemiological analysis, qualitative foot-and-mouth disease virus type O and type A antibody detection of in vitro serum, international live pig, cattle and sheep trade, import and export inspection and quarantine, and foot-and-mouth disease virus type O and type A vaccine quality control.

Citation Information

Patent Citations

  • Anti-foot-and-mouth disease vaccine composition and preparation method and application thereof

    CN105566449A

  • A monoclonal antibody against foot-and-mouth disease virus and its uses

    CN102277332A

  • Type A foot-and-mouth disease virus monoclonal antibody and application thereof

    CN107541500A

  • Double rapid test strip for detecting and identifying type O and A foot and mouth disease viruses and preparation method thereof

    CN109187967A

  • Hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus, the monoclonal antibody therefrom, immunoassay reagent and kit, and immunoassay method

    US20110014639A1